Perbak Capital Partners’s Moderna MRNA Stock Holding History

Perbak Capital Partners’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,991	Closed	-$558K	–	155
2026 Q1	$558K	Buy	+10,991	New	+$513K	0.14%	171

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Perbak Capital Partners's MRNA Position: Q2 2026 in Review

Perbak Capital Partners sold out of Moderna (MRNA) in Q2 2026, closing a stake of 10,991 shares — an estimated $558K sold.

Perbak Capital Partners first reported a position in MRNA in Q1 2026 and held it in 1 quarter. The position peaked at $558K in Q1 2026. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Perbak Capital Partners reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
Perbak Capital Partners sold 10,991 Moderna shares in Q2 2026, an estimated $558K.
Perbak Capital Partners first reported a position in Moderna in Q1 2026 and held it in 1 quarter.
Perbak Capital Partners's Moderna position peaked at $558K in Q1 2026.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.